JP2008510682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008510682A5 JP2008510682A5 JP2007521717A JP2007521717A JP2008510682A5 JP 2008510682 A5 JP2008510682 A5 JP 2008510682A5 JP 2007521717 A JP2007521717 A JP 2007521717A JP 2007521717 A JP2007521717 A JP 2007521717A JP 2008510682 A5 JP2008510682 A5 JP 2008510682A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- och
- cycloalkyl
- compound
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 53
- 150000001875 compounds Chemical class 0.000 claims 49
- 229910052799 carbon Inorganic materials 0.000 claims 32
- 229910052757 nitrogen Inorganic materials 0.000 claims 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims 26
- 229910052760 oxygen Inorganic materials 0.000 claims 23
- 229910052717 sulfur Inorganic materials 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 19
- 239000012453 solvate Substances 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 125000003342 alkenyl group Chemical group 0.000 claims 17
- 125000000304 alkynyl group Chemical group 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 14
- -1 aryloxyalkyl sulfonamide Chemical class 0.000 claims 11
- 229940124530 sulfonamide Drugs 0.000 claims 11
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims 9
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 6
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 6
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 125000004104 aryloxy group Chemical group 0.000 claims 5
- 229940079322 interferon Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000014150 Interferons Human genes 0.000 claims 4
- 108010050904 Interferons Proteins 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052698 phosphorus Inorganic materials 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 3
- 208000005176 Hepatitis C Diseases 0.000 claims 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 3
- 125000002837 carbocyclic group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 150000003949 imides Chemical class 0.000 claims 3
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 239000002777 nucleoside Substances 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 150000003456 sulfonamides Chemical class 0.000 claims 3
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 claims 1
- TZYVRXZQAWPIAB-FCLHUMLKSA-N 5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950003954 isatoribine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 1
- 229950006081 taribavirin Drugs 0.000 claims 1
- 0 CCC*C(C(CC(C1)N)*1C(C(*)(*)*(*)*)=O)=N Chemical compound CCC*C(C(CC(C1)N)*1C(C(*)(*)*(*)*)=O)=N 0.000 description 4
- SGHBRHKBCLLVCI-UHFFFAOYSA-N N#Cc1cc(O)ccc1 Chemical compound N#Cc1cc(O)ccc1 SGHBRHKBCLLVCI-UHFFFAOYSA-N 0.000 description 2
- VLVXVXHLNSXLAY-OMIVJXSDSA-O CC(C)CCc1nc(-c2cc(O[C@H](C[C@H]3C(N[C@](C4)([C@@H]4C=C)[O](Oc4ccccc4)(Oc4ccccc4)=O)=O)CN3C([C@H](C(C)(C)C)NC(OC3CCCC3)=[OH+])=O)c(ccc([O-]C)c3)c3n2)c[s]1 Chemical compound CC(C)CCc1nc(-c2cc(O[C@H](C[C@H]3C(N[C@](C4)([C@@H]4C=C)[O](Oc4ccccc4)(Oc4ccccc4)=O)=O)CN3C([C@H](C(C)(C)C)NC(OC3CCCC3)=[OH+])=O)c(ccc([O-]C)c3)c3n2)c[s]1 VLVXVXHLNSXLAY-OMIVJXSDSA-O 0.000 description 1
- ZSYWAFVGVGVJLG-HZUVPCQBSA-N CC(C)Nc1nc(-c2cc(O[C@H](C[C@H]3C(N[C@](C4)([C@@H]4C=C)C=O)=O)CN3C([C@H](C(C)(C)C)NC(OC3CCCC3)=O)=O)c(ccc(OC)c3)c3n2)c[s]1 Chemical compound CC(C)Nc1nc(-c2cc(O[C@H](C[C@H]3C(N[C@](C4)([C@@H]4C=C)C=O)=O)CN3C([C@H](C(C)(C)C)NC(OC3CCCC3)=O)=O)c(ccc(OC)c3)c3n2)c[s]1 ZSYWAFVGVGVJLG-HZUVPCQBSA-N 0.000 description 1
- XPIFPNHIJGCYJC-UHFFFAOYSA-N OCOc1cccc(Cl)c1 Chemical compound OCOc1cccc(Cl)c1 XPIFPNHIJGCYJC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58863304P | 2004-07-16 | 2004-07-16 | |
| US60/588,633 | 2004-07-16 | ||
| US59163504P | 2004-07-27 | 2004-07-27 | |
| US60/591,635 | 2004-07-27 | ||
| PCT/US2005/025503 WO2006020276A2 (en) | 2004-07-16 | 2005-07-18 | Antiviral compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012023052A Division JP5767984B2 (ja) | 2004-07-16 | 2012-02-06 | 抗ウイルス化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008510682A JP2008510682A (ja) | 2008-04-10 |
| JP2008510682A5 true JP2008510682A5 (enExample) | 2008-08-07 |
| JP5676839B2 JP5676839B2 (ja) | 2015-02-25 |
Family
ID=35447172
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007521717A Expired - Fee Related JP5676839B2 (ja) | 2004-07-16 | 2005-07-18 | 抗ウイルス化合物 |
| JP2012023052A Expired - Fee Related JP5767984B2 (ja) | 2004-07-16 | 2012-02-06 | 抗ウイルス化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012023052A Expired - Fee Related JP5767984B2 (ja) | 2004-07-16 | 2012-02-06 | 抗ウイルス化合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20080311077A1 (enExample) |
| EP (2) | EP1778702B1 (enExample) |
| JP (2) | JP5676839B2 (enExample) |
| KR (1) | KR20070034119A (enExample) |
| AP (1) | AP2461A (enExample) |
| AR (1) | AR050174A1 (enExample) |
| AT (1) | ATE516293T1 (enExample) |
| AU (1) | AU2005274700B2 (enExample) |
| BR (1) | BRPI0513426A (enExample) |
| CA (1) | CA2571984C (enExample) |
| CY (1) | CY1112453T1 (enExample) |
| DK (1) | DK1778702T3 (enExample) |
| EA (1) | EA200700336A1 (enExample) |
| ES (1) | ES2468441T3 (enExample) |
| HR (2) | HRP20070043A2 (enExample) |
| IL (1) | IL180288A0 (enExample) |
| MX (1) | MX2007000584A (enExample) |
| NO (1) | NO20070866L (enExample) |
| NZ (1) | NZ552405A (enExample) |
| PL (2) | PL1778702T3 (enExample) |
| PT (1) | PT1778702E (enExample) |
| RS (1) | RS51974B (enExample) |
| TW (2) | TW200614996A (enExample) |
| WO (1) | WO2006020276A2 (enExample) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| US7273851B2 (en) * | 2003-06-05 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | Tri-peptide hepatitis C serine protease inhibitors |
| US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) * | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| NZ565059A (en) | 2005-07-25 | 2011-08-26 | Intermune Inc | Novel macrocyclic inhibitors of hepatitus C virus replication |
| BRPI0617274A2 (pt) | 2005-10-11 | 2011-07-19 | Intermune Inc | compostos e métodos para a inibição de replicação viral de hepatite c |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PL1966130T3 (pl) | 2005-12-23 | 2014-05-30 | Zealand Pharma As | Zmodyfikowane związki mimetyczne lizyny |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| CN101489564A (zh) * | 2006-07-07 | 2009-07-22 | 吉里德科学公司 | 抗病毒的次膦酸酯化合物 |
| ATE554776T1 (de) * | 2006-07-07 | 2012-05-15 | Gilead Sciences Inc | Antivirale phosphinatverbindungen |
| AU2013200563C1 (en) * | 2006-07-07 | 2015-05-14 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
| EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| PT2041156E (pt) | 2006-07-13 | 2014-02-21 | Achillion Pharmaceuticals Inc | Péptidos 4-amino-4-oxobutanoil como inibidores da replicação viral |
| US20090035271A1 (en) * | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| CA2656816A1 (en) * | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| US7582605B2 (en) * | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
| CA2663159A1 (en) * | 2006-09-13 | 2008-03-20 | Novartis Ag | Organic compounds and their uses |
| AU2007309546A1 (en) * | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008070358A2 (en) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ES2558856T3 (es) | 2006-12-21 | 2016-02-09 | Zealand Pharma A/S | Síntesis de compuestos de pirrolidina |
| US20080161254A1 (en) * | 2007-01-03 | 2008-07-03 | Virobay, Inc. | Hcv inhibitors |
| WO2008096002A1 (en) * | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
| RU2490261C2 (ru) * | 2007-02-08 | 2013-08-20 | Тиботек Фармасьютикалз Лтд. | Макроциклические фенилкарбаматы, ингибирующие hcv |
| US20080267917A1 (en) * | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
| WO2008134397A1 (en) * | 2007-04-26 | 2008-11-06 | Enanta Pharmaceuticals, Inc. | Aza-tripeptide hepatitis c serine protease inhibitors |
| AU2008251425A1 (en) | 2007-05-10 | 2008-11-20 | Array Biopharma, Inc. | Novel peptide inhibitors of hepatitis C virus replication |
| AU2014200403B2 (en) * | 2007-06-29 | 2016-05-19 | Gilead Sciences, Inc. | Antiviral compounds |
| MX2009013827A (es) * | 2007-06-29 | 2010-03-01 | Gilead Sciences Inc | Compuestos antivirales. |
| US20090047252A1 (en) * | 2007-06-29 | 2009-02-19 | Gilead Sciences, Inc. | Antiviral compounds |
| US8513186B2 (en) * | 2007-06-29 | 2013-08-20 | Gilead Sciences, Inc. | Antiviral compounds |
| US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| WO2009064955A1 (en) | 2007-11-14 | 2009-05-22 | Enanta Pharmaceuticals, Inc. | Macrocyclic tetrazolyl hepatitis c serine protease inhibitors |
| WO2009070689A1 (en) * | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
| WO2009070692A1 (en) * | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
| WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
| WO2009082697A1 (en) | 2007-12-21 | 2009-07-02 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| TW201546079A (zh) | 2007-12-21 | 2015-12-16 | Celgene Avilomics Res Inc | Ｈｃｖ蛋白酶抑制劑及其用途（一） |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| US8003659B2 (en) | 2008-02-04 | 2011-08-23 | Indenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8372802B2 (en) | 2008-03-20 | 2013-02-12 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors |
| CA2720729A1 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102046648A (zh) | 2008-05-29 | 2011-05-04 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR101762842B1 (ko) | 2008-12-10 | 2017-08-04 | 아칠리온 파르마세우티칼스 인코포레이티드 | 바이러스 복제 억제제로서 유용한 신규한 4-아미노-4-옥소부타노일 펩티드 |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| WO2010118078A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| BRPI1010795B1 (pt) | 2009-05-13 | 2018-12-11 | Gilead Pharmasset Llc | compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos |
| KR20100127948A (ko) * | 2009-05-27 | 2010-12-07 | 한국전자통신연구원 | Ｓａｒｓ 코로나바이러스의 검출 및 억제용 펩타이드 화합물 및 그의 응용 |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| US7924650B2 (en) * | 2009-06-30 | 2011-04-12 | Oracle America, Inc. | Dynamically controlled voltage regulator for a memory |
| WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| US8927484B2 (en) * | 2009-12-03 | 2015-01-06 | Gilead Sciences, Inc. | Antiviral compounds |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| SG10201509456SA (en) | 2010-11-17 | 2015-12-30 | Gilead Pharmasset Llc | Antiviral compounds |
| EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
| MX2013007698A (es) | 2010-12-30 | 2013-08-15 | Abbvie Inc | Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina. |
| US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| AR086492A1 (es) * | 2011-05-19 | 2013-12-18 | Gilead Sciences Inc | Procedimientos e intermediarios para preparar agentes anti-hiv |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| SMT201800470T1 (it) | 2011-11-16 | 2018-11-09 | Gilead Pharmasset Llc | Imidazolilimidazoli condensati come composti antivirali |
| US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| JP2015533124A (ja) | 2012-10-08 | 2015-11-19 | アッヴィ・インコーポレイテッド | Ｈｃｖプロテアーゼ阻害剤を作製するのに有用な化合物 |
| WO2014062196A1 (en) | 2012-10-19 | 2014-04-24 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| CN105164148A (zh) | 2013-03-07 | 2015-12-16 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| WO2014145600A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof |
| WO2014145507A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
| US9227952B2 (en) | 2013-03-15 | 2016-01-05 | Achillion Pharmaceuticals, Inc. | Sovaprevir polymorphs and methods of manufacture thereof |
| JP6511432B2 (ja) | 2013-03-15 | 2019-05-15 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃ型肝炎ウイルスの大環状二環式阻害剤 |
| US9962251B2 (en) | 2013-10-17 | 2018-05-08 | Boston Scientific Scimed, Inc. | Devices and methods for delivering implants |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| EA201892375A1 (ru) | 2016-05-27 | 2019-08-30 | Джилид Сайэнс, Инк. | Способы лечения инфекций, вызываемых вирусом гепатита b |
| DK3618847T3 (da) | 2017-05-05 | 2021-05-25 | Boston Medical Ct Corp | GAP-junction-modulatorer af intercellulær kommunikation og deres anvendelse til behandling af diabetisk øjensygdom |
| ES2969496T3 (es) | 2017-08-01 | 2024-05-20 | Gilead Sciences Inc | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| CN110892989B (zh) * | 2019-06-27 | 2023-03-14 | 内蒙古伊利实业集团股份有限公司 | 一种具有缓解便秘功能的副干酪乳杆菌et-22 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) * | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| ATE131825T1 (de) | 1990-06-13 | 1996-01-15 | Arnold Glazier | Phosphorylierte prodrugs |
| EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| DE69709671T2 (de) * | 1996-10-18 | 2002-08-22 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus |
| EP0994106B1 (en) * | 1996-12-26 | 2004-03-17 | Shionogi & Co., Ltd. | Process for the preparation of carbamoylated imidazole derivatives |
| AU757783B2 (en) * | 1997-08-11 | 2003-03-06 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| PE20020707A1 (es) * | 2000-11-20 | 2002-08-11 | Bristol Myers Squibb Co | Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c |
| CZ20032001A3 (en) * | 2001-01-31 | 2004-06-16 | Warner-Lambert Company Llc | Method for carbamoylating alcohols |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2369711A1 (en) * | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| ES2361011T3 (es) * | 2002-05-20 | 2011-06-13 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c. |
| ATE481106T1 (de) * | 2002-05-20 | 2010-10-15 | Bristol Myers Squibb Co | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer |
-
2005
- 2005-07-18 MX MX2007000584A patent/MX2007000584A/es active IP Right Grant
- 2005-07-18 EA EA200700336A patent/EA200700336A1/ru unknown
- 2005-07-18 BR BRPI0513426-9A patent/BRPI0513426A/pt not_active IP Right Cessation
- 2005-07-18 PT PT05791144T patent/PT1778702E/pt unknown
- 2005-07-18 KR KR1020077003918A patent/KR20070034119A/ko not_active Abandoned
- 2005-07-18 PL PL05791144T patent/PL1778702T3/pl unknown
- 2005-07-18 US US11/632,180 patent/US20080311077A1/en not_active Abandoned
- 2005-07-18 EP EP05791144A patent/EP1778702B1/en not_active Expired - Lifetime
- 2005-07-18 US US11/184,429 patent/US7642339B2/en active Active
- 2005-07-18 HR HR20070043A patent/HRP20070043A2/xx not_active Application Discontinuation
- 2005-07-18 ES ES10178084.9T patent/ES2468441T3/es not_active Expired - Lifetime
- 2005-07-18 AR ARP050102967A patent/AR050174A1/es not_active Application Discontinuation
- 2005-07-18 JP JP2007521717A patent/JP5676839B2/ja not_active Expired - Fee Related
- 2005-07-18 AU AU2005274700A patent/AU2005274700B2/en not_active Ceased
- 2005-07-18 RS RS20110436A patent/RS51974B/sr unknown
- 2005-07-18 EP EP10178084.9A patent/EP2316839B1/en not_active Expired - Lifetime
- 2005-07-18 NZ NZ552405A patent/NZ552405A/en not_active IP Right Cessation
- 2005-07-18 PL PL382845A patent/PL382845A1/pl not_active Application Discontinuation
- 2005-07-18 WO PCT/US2005/025503 patent/WO2006020276A2/en not_active Ceased
- 2005-07-18 AP AP2007003895A patent/AP2461A/xx active
- 2005-07-18 DK DK05791144.8T patent/DK1778702T3/da active
- 2005-07-18 CA CA2571984A patent/CA2571984C/en not_active Expired - Fee Related
- 2005-07-18 HR HR20110732T patent/HRP20110732T1/hr unknown
- 2005-07-18 AT AT05791144T patent/ATE516293T1/de active
- 2005-07-19 TW TW094124376A patent/TW200614996A/zh unknown
- 2005-07-19 TW TW101104372A patent/TW201228665A/zh unknown
-
2006
- 2006-12-25 IL IL180288A patent/IL180288A0/en unknown
-
2007
- 2007-02-15 NO NO20070866A patent/NO20070866L/no not_active Application Discontinuation
-
2011
- 2011-10-10 CY CY20111100970T patent/CY1112453T1/el unknown
-
2012
- 2012-02-06 JP JP2012023052A patent/JP5767984B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008510682A5 (enExample) | ||
| JP2009501724A5 (enExample) | ||
| CA2571984A1 (en) | Antiviral compounds | |
| JP2005535574A5 (enExample) | ||
| JP2004533401A5 (enExample) | ||
| JP2003501474A5 (enExample) | ||
| CA2409613A1 (en) | Methods and compositions for treating hepatitis c virus | |
| JP2007532474A5 (enExample) | ||
| RU2010111551A (ru) | Замещенные индольные производные и способы их применения | |
| RU2005100053A (ru) | Азуленовое производное и его соль | |
| RU2008152087A (ru) | Макроциклические оксимильные ингибиторы протеазы гепатита | |
| CA2516018A1 (en) | Hepatitis c inhibitor peptide analogs | |
| RU2012136379A (ru) | 4'-азидонуклеозиды, активные в отношении hcv | |
| RU2003134544A (ru) | Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции | |
| BRPI1012781A8 (pt) | N-[(2'r)-2'-deóxi-2'-fluor-2'-metil-p-fenil-5'-uridil]-l-alanina 1-metiletil éster e processo para sua produção | |
| JP2013056886A5 (enExample) | ||
| RU2002121628A (ru) | Нуклеозидные соединения и их применение | |
| JP2005533824A5 (enExample) | ||
| JP2020534374A5 (enExample) | ||
| CA2540858A1 (en) | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication | |
| JP2010505902A5 (enExample) | ||
| CY1112254T1 (el) | Αρυλικοι φωσφοραμιδικοι εστερες νουκλεοζιτων και οι χρησεις τους ως αντι-ιικοι παραγοντες για την αντιμετωπιση του ιου της ηπατιτιδας c | |
| EP2311851A3 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| JP2005539088A5 (enExample) | ||
| RU2009141187A (ru) | Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с |